JPLA
NBRV

Joseph P. Lucia & Associates’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Joseph P. Lucia & Associates’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1
Closed – – 477
2022
Q2 		$0 Hold
1
– – ﹤0.01% 527
2022
Q1 		$0 Buy
+1
New +$12 ﹤0.01% 482
2021
Q4 		– Sell
-1
Closed – – 600
2021
Q3 		$0 Hold
1
– – ﹤0.01% 637
2021
Q2 		$0 Hold
1
– – ﹤0.01% 645
2021
Q1 		$0 Hold
1
– – ﹤0.01% 634
2020
Q4 		$0 Buy
+1
New +$108 ﹤0.01% 511
2020
Q3 		– Sell
-1
Closed – – 495
2020
Q2 		$0 Buy
+1
New +$167 ﹤0.01% 516

Other funds holding NBRV

VFA
Values First Advisors Gray, Tennessee $219M AUM 33.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Joseph P. Lucia & Associates's NBRV Position: Q3 2022 in Review

Joseph P. Lucia & Associates sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q3 2022, closing a stake of 1 share.

Joseph P. Lucia & Associates first reported a position in NBRV in Q2 2020 and held it in 7 quarters. The position peaked at $0 in Q2 2022. 13 funds tracked by Wall St. Rank hold NBRV as of Q3 2022.

  • Joseph P. Lucia & Associates reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q3 2022 after selling out during the quarter.
  • Joseph P. Lucia & Associates sold 1 Nabriva Therapeutics plc Ordinary Shares Ireland share in Q3 2022.
  • Joseph P. Lucia & Associates first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q2 2020 and held it in 7 quarters.
  • Joseph P. Lucia & Associates's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $0 in Q2 2022.
  • 13 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q3 2022.

Based on Joseph P. Lucia & Associates's 13F filing for Q3 2022, filed 28 Oct 2022.